Dabigatran

Mechanism of action

Anticoagulant (direct thrombin inhibitor).

Inhibits formation of fibrin by direct inhibition of thrombin.

Indications and dose

Side-effects

Anaemia

Bleeding

Precautions

Contraindicated in patients with CrCl < 30 ml/min.

Consider reducing thedose if concurrent use of amiodarone, fungostatics or ritonavir.

Reversal agent

Idarucizumab (brand name Praxbind)

Pharmacokinetics

Routes: Oral

Onset: 1 hour

Bioavailability: 3-7% 

Metabolism: Hepatic

Half-life of elimination: 12-17 hours

Excretion:  Urine

Medicinal forms

Capsules - 110 mg and 150 mg.

‍

References

https://bnf.nice.org.uk/drugs/dabigatran-etexilate/ 

https://litfl.com/dabigatran-and-bleeding/ 

https://www.uptodate.com/contents/dabigatran-drug-information?search=dabigatran&source=panel_search_result&selectedTitle=1~148&usage_type=panel&kp_tab=drug_general&display_rank=1 

https://www.nice.org.uk/donotdo/do-not-withhold-anticoagulation-solely-because-the-person-is-at-risk-of-having-afall